Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

WEDNESDAY EVENING — AUGUST 26, 2026

Core inflation held at 3.3 percent, the tape spent the day going nowhere, and Nvidia reports after the bell

The two scheduled events of the day arrived in order. The July personal consumption expenditures price index landed at 8:30 a.m. ET and left annual core inflation exactly where it was, and Nvidia’s fiscal second quarter is due after the close. Between the two the American session has traded flat: the four index proxies are within a quarter of a point of Tuesday’s close in either direction. U.S. cash markets were still open when this page was written, so every American figure below is a live intraday mark read at 14:05 ET (20:05 in Rome) and compared with the August 25 close, not a settlement price.

WHAT THE DATA SAID
  • The July PCE price index rose 0.2 percent from June and 3.7 percent from a year earlier. Excluding food and energy it also rose 0.2 percent on the month and 3.3 percent on the year. Both annual rates are the same figures the Bureau of Economic Analysis published for June, so the month added no new direction.PCE
  • Underneath the index, personal income rose 115.1 billion dollars, or 0.4 percent, disposable personal income 125.9 billion dollars, or 0.5 percent, and consumer spending 36.3 billion dollars, or 0.2 percent. Real spending rose 1.3 billion dollars, less than a tenth of a percent, so almost the whole nominal increase was price.INCOME
  • The composition is the part worth keeping: services spending rose 86.2 billion dollars while goods spending fell 49.9 billion dollars. The personal saving rate was 3.0 percent, on saving of 712.0 billion dollars.MIX
  • The second estimate of second-quarter gross domestic product held at an annual rate of 1.5 percent, unchanged from the advance reading. An upward revision to consumer spending was offset by an upward revision to imports.GDP
  • July durable goods orders rose 3.6 billion dollars, or 1.1 percent, to 339.3 billion dollars, after a 0.5 percent June increase. Excluding transportation the gain was 0.4 percent and excluding defense 1.3 percent, with transportation equipment up 2.3 percent to 116.2 billion dollars.ORDERS
THE TAPE AT 14:05 ET
  • $SPY 765.60 (-0.04%), $QQQ 710.94 (+0.03%), $DIA 534.01 (-0.23%), $IWM 298.92 (-0.10%). The whole spread between best and worst proxy is roughly a quarter of a point, which is what a market waiting for a single earnings report looks like.INDEXES
  • The leadership is in the parts of the tape that have nothing to do with tonight’s print: $XLI 180.21 (+1.01%), $XLE 62.56 (+0.80%), $XLU 43.53 (+0.51%) and $XLK 182.60 (+0.47%) against $XLV 173.73 (-0.89%), $XLP 86.36 (-0.18%) and $XLF 58.24 (-0.12%).SECTORS
  • $SMH 555.13 (-0.12%) and $SOXX 514.48 (+0.08%). The semiconductor complex, which led Tuesday’s session, is flat on the day it matters most.SEMIS
  • $TLT 83.17 (-0.36%) and $GLD 421.99 (-1.42%). Long duration and gold both gave ground, the second session in a row that the two have moved together rather than against each other.RATES
  • $USO 128.08 (+1.53%) and $UNG 10.40 (+1.66%). Crude turned back up after three sessions of decline, having been sharply lower before the New York open.CRUDE
AI, SEMIS AND DATA CENTRE
  • $SMTC 139.21 (+9.16%) is the strongest chip name of the session after a second quarter above estimates and third-quarter guidance above estimates. $SIMO 256.38 (+6.02%) is behind it.CHIPS
  • The optical and networking side carried more than the chips themselves: $LITE 940.47 (+6.20%) and $ANET 200.48 (+5.00%). $ORCL 148.16 (+2.35%), $PLTR 176.48 (+2.17%) and $META 578.61 (+1.50%) are the large names on the same side.NETWORK
  • Large chips were mixed and small: $AMD 482.86 (+0.77%), $MU 940.61 (+0.82%), $MRVL 243.65 (+1.36%), $TSM 418.05 (+0.15%), against $AVGO 353.21 (-0.99%) and $ASML 1,741.07 (-0.18%).MEGACHIP
  • The build-out names went the other way. $DY 312.72 (-11.11%) is the largest decline on the board after its quarter, and $APLD 27.38 (-5.11%) followed. The two are the physical side of the same capital expenditure the market is about to hear described.BUILD
  • Software guidance did the damage elsewhere: $INTU 343.22 (-3.98%) after a fiscal 2027 outlook below estimates, $ZM 94.65 (-6.21%) after soft third-quarter guidance. Both reported upbeat quarters and were sold on the forward number.GUIDANCE
BIOTECH AND HEALTHCARE
  • $BHVN 18.07 (+25.63%) is the largest move in the sector. Biohaven’s Irish subsidiary licensed its Kv7 ion channel platform, led by opakalim, to SK Biopharmaceuticals: 400 million dollars in upfront cash, of which 350 million at closing and 50 million one year later, plus up to 395 million in development and regulatory milestones, for a stated total of up to 795 million. The agreement was filed on a Form 8-K dated August 26.LICENSE
  • The economics behind that headline matter more than the headline: SK Biopharmaceuticals takes an exclusive worldwide licence and Biohaven keeps tiered royalties on U.S. net sales described as running from the mid-teens to the low twenties. Opakalim is in Phase 2/3 for focal epilepsy and the company points to RISE3 topline data in the second half of 2026.TERMS
  • $SMMT 14.65 (+9.65%) after partner Akeso reported that ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in the Phase III HARMONi-GI1 study in first-line advanced biliary tract cancer, also meeting key secondary endpoints on progression-free survival and response rate. The trial was run in China; Summit holds rights outside that territory.DATA
  • $CAPR 9.12 (+9.96%). The deramiocel target action date now sits at November 22, 2026 following the three-month extension the company disclosed on August 24. A target date can resolve before, on or after the stated day.PDUFA
  • Elsewhere on the long side: $APMD 30.00 (+9.61%), $ERAS 19.08 (+7.43%), $ALHC 14.37 (+5.74%), $AVTX 20.82 (+5.46%), $AQST 5.36 (+5.41%).MOVERS
  • The declines were larger than the advances: $GENB 16.76 (-17.74%), $CLYM 16.24 (-8.97%), $AVXL 3.29 (-7.70%) after Monday’s fiscal third quarter, $ENTX 3.21 (-7.49%), $ACRS 6.12 (-6.27%), $HIMS 29.86 (-5.94%).DECLINES
  • $XBI 168.57 (-0.31%) against $XLV 173.73 (-0.89%). Small and mid-cap biotech is holding better than large healthcare for the second session, but neither is contributing to the index.SPREAD
ENERGY, NUCLEAR AND CRITICAL MINERALS
  • Refining is the strongest energy sub-group of the day: $CVI 40.46 (+6.79%), $PBF 70.06 (+5.34%), $DK 70.98 (+5.02%), with $XLE 62.56 (+0.80%) behind them.REFINERS
  • Nuclear went the other way and did it on volume. $SMR 9.07 (-7.49%) on roughly 34.8 million shares, $OKLO 41.44 (-6.40%) on about 13.0 million. $LEU 186.00 (-3.82%) and $UEC 13.02 (-1.92%) followed, while $CCJ 107.47 (+0.48%) held and $URA 48.01 (-0.27%) barely moved.NUCLEAR
  • Solar was the exception inside a weak clean-energy tape: $SEDG 32.04 (+7.23%) on an upgrade and $SHLS 7.23 (+4.96%), the latter after announcing a favourable outcome in a patent proceeding.SOLAR
  • Critical minerals gave back ground: $USAR 18.84 (-2.94%) and $MP 58.75 (-2.36%), both against a broad industrial complex that rose.MINERALS
SPACE AND DEFENCE
  • The split inside the sector is the clearest single divergence on the board. Primes higher: $LMT 565.08 (+1.54%), $NOC 550.77 (+1.52%), $RTX 211.16 (+0.42%), with $KTOS 52.71 (+0.12%) and $AVAV 147.44 (+0.01%) flat.PRIMES
  • Space small caps lower across the board: $LUNR 15.93 (-4.07%), $ASTS 59.93 (-3.35%), $SATL 5.18 (-3.19%), $PL 21.14 (-1.91%), $RDW 11.32 (-1.42%), $RKLB 66.48 (-0.64%). $SPCX 137.91 (-0.03%) was unchanged on heavy turnover.SMALL CAPS
TRADE AND THE BACKDROP
  • Canada set out its counter-measures on Tuesday: duties on about 27.6 billion Canadian dollars, near 20 billion U.S. dollars, of American goods across more than 700 product lines, in bands of 15, 25 and 50 percent, effective at 12:01 a.m. on September 8. Ottawa paired them with a 7.5 billion Canadian dollar support package. These are the goods prices the inflation series reads.TARIFFS
  • On the energy side of geopolitics, Iran and Oman have been discussing a temporary joint navigational corridor through the Strait of Hormuz, and the United States has begun returning personnel to diplomatic posts in Lebanon, Israel and Saudi Arabia. That is the backdrop to crude turning up after three sessions down.HORMUZ
  • Rate expectations remain the awkward part of the picture. On Wednesday morning the CME FedWatch tool put roughly a 36 percent probability on the Federal Reserve raising rates at the September meeting, not cutting. Core inflation staying at 3.3 percent does not move that debate in either direction.FED
AFTER THE CLOSE
  • $NVDA 210.50 (-1.20%) heading into its own report. Published Street consensus is around 2.09 dollars a share on roughly 92.0 billion dollars of revenue for the fiscal second quarter. The company has beaten repeatedly and the stock has frequently been sold afterwards, so the reaction is a separate question from the numbers.TONIGHT
  • The two things worth reading in the release rather than the headline: how much of the revenue is concentrated in a handful of hyperscale customers, and what the guidance implies for the build-out names that fell today.WATCH
  • Next scheduled macro checkpoint on this series is the August personal income and outlays release on September 30, which arrives together with the annual update of the national accounts.CALENDAR
METHOD

U.S. equity and ETF prices are live intraday marks read at 14:05 ET on Wednesday, August 26, 2026 from the Finviz Elite feed, with percentage changes measured against the August 25 official close; U.S. cash markets had not closed when this page was written. The July personal income, spending and PCE price figures and the second estimate of second-quarter gross domestic product are taken from the Bureau of Economic Analysis releases of August 26; the durable goods figures from the Census Bureau advance report of the same morning. The Biohaven terms are taken from the company’s Form 8-K dated August 26 and its own release; the Summit and Akeso results from the partner announcement of August 25; the Capricor target action date from the company’s release of August 24. Tariff details are as published by the Canadian federal government. The Nvidia consensus and the September rate probability are published third-party figures as of Wednesday morning and are labelled as such. This page is educational research, not investment advice and not a recommendation to buy or sell any security; readers should do their own work and consult a licensed adviser.

Read the extended Daily BriefingWeekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: August 25 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory process is still materially open; catalysts resolved in the past few days are retained briefly for continuity. October and later events are excluded from this widget.

29On board
14FDA / Reg
15Data / Filing
Aug 26Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$JAZZ Ziihera combo Aug 25 Approved FDA approval in first-line HER2-positive GEA

Jazz Pharmaceuticals. On August 25, 2026 the FDA approved Ziihera (zanidatamab-hrii) in two first-line regimens for locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma: with tislelizumab and fluoropyrimidine- and platinum-based chemotherapy for IHC 3+ and IHC 2+/ISH+ tumours, and with chemotherapy alone for IHC 3+ tumours. The decision landed on the Priority Review goal date. Approval rests on the Phase 3 HERIZON-GEA-01 trial, where median progression-free survival was 12.4 months against 8.1 months and median overall survival 26.4 months against 19.2 months. The label carries a boxed warning for diarrhoea and embryo-fetal toxicity. Zanidatamab was discovered by Zymeworks ($ZYME), which confirmed the approval the same day.

$NRXP KETAFREE Ongoing FDA review First-cycle review complete; manufacturer vial attestation submitted

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the ANDA remains active. On August 7 the company reported that FDA had completed its first-cycle review of the preservative-free intravenous ketamine ANDA with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related review matters. The sole remaining major deficiency involved the container-closure system and a manufacturer attestation concerning the luer-lock vial. The same vial is used in three approved ANDA products that collectively shipped 11.9 million units in the United States over the prior 12 months, and the filing included testing of more than 3,500 vials from seven lots without observed luer-lock failures. On August 17 NRx confirmed that the requested attestation had been submitted. No company release has followed since August 17 and no new exact action date has been disclosed.

$GILD BIC/LEN Aug 27 NDA Once-daily oral HIV regimen · decision due this week

Gilead. Priority Review PDUFA for the bictegravir 75 mg and lenacapavir 50 mg NDA, a once-daily single-tablet regimen for virologically suppressed adults with HIV, supported by the ARTISTRY-1 and ARTISTRY-2 studies. No approval, extension or complete response letter had been announced as of August 25, so the decision remains due within days. It is a lifecycle catalyst for the HIV franchise rather than a first entry into the class.

$PTGX rusfertide Aug NDA Polycythemia vera · company guidance now says August, and no decision has been announced

Protagonist / Takeda. The rusfertide NDA in polycythemia vera is under Priority Review and no FDA decision had been announced as of August 25. The most recent primary-source wording is narrower than the original one: Protagonist’s second-quarter release and Form 10-Q, both dated August 5, 2026, state that the application carries “a Prescription Drug User Fee Act target action date in August 2026”. The earlier joint Takeda and Protagonist announcement of March 2, 2026 had placed the goal date in the third quarter without naming a month. The exact day has never been made public, so the window is closing, or has closed, without an announcement. Rusfertide also holds Breakthrough Therapy, Orphan Drug and Fast Track designations, and the submission rests on the Phase 3 VERIFY study with the Phase 2 REVIVE study and the THRIVE long-term extension.

$TLX Pixclara Sep 11 PDUFA FDA decision on the resubmitted Pixclara NDA

Telix Pharmaceuticals. September 11, 2026 is the FDA goal date for the resubmitted Pixclara (TLX101-Px) NDA, reconfirmed by the company in the half-year announcement filed on Form 6-K on August 20, 2026. The application was resubmitted in March and accepted in April, so the September catalyst is the decision on that NDA, not the filing itself. Pixclara is a PET imaging agent intended to help characterise suspected recurrent or progressive glioma against treatment-related changes. In the same document Telix confirmed that the Zircaix BLA has still to be resubmitted.

$RARE UX111 Sep 19 BLA Gene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A, seeking accelerated approval. The date was set with the acceptance of the BLA resubmission and the company reaffirmed it in its August 4 update; no extension has been announced since. The August 19 accelerated approval of GENGLYCOS in glycogen storage disease type Ia is a separate programme and does not change this review.

$MRK WINREVAIR Sep 21 sBLA PAH · HYPERION-based label update

Merck. PDUFA for a supplemental BLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. The September 21 date is stated in the Form 10-Q filed on August 7, 2026, and nothing published since changes it.

$IONS zilganersen Sep 22 NDA Alexander disease · Priority Review

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. The date is confirmed in the Form 10-Q filed on July 29, 2026. Ionis is preparing to commercialise the product itself in the United States, while ex-U.S. rights were licensed to Recordati in June 2026. It remains one of September’s most closely watched rare-disease decisions.

$GRAL Galleri Sep 23 FDA panel AdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel is scheduled to meet on September 23, 2026 to discuss and vote on the Galleri premarket approval application. The meeting notice was published in the Federal Register on August 10, 2026, the session runs from 9:00 to 18:00 Eastern at White Oak in hybrid form, and public comments close on September 8. The FDA advisory committee calendar still carries the meeting with no postponement note. Galleri is a blood-based multi-cancer early detection test proposed for adults aged 50 and older; this is a device and diagnostics catalyst rather than a drug PDUFA, and it is the first FDA advisory committee ever convened on an MCED test.

$MIRM zilurgisertib Sep 26 NDA FOP · NDA rests on secondary endpoints

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 and older; the application is Incyte’s and Mirum holds exclusive worldwide rights under a licence signed in April 2026, with 25 million dollars due on FDA approval. The date is confirmed in Mirum’s Form 10-Q of August 5, 2026. The same filing states in its risk factors that “while the NDA for zilurgisertib is supported by secondary endpoints, the pivotal study did not reach statistical significance on the primary endpoint”. That pivotal study is the Phase 2 PROGRESS trial, whose results the company presented at ENDO 2026 without addressing the primary endpoint.

$BFRI Ameluz PDT Sep 28 sNDA Expansion into superficial basal cell carcinoma

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. The date comes from the filing-acceptance release of February 11, 2026, in which FDA identified no filing deficiencies, and the company reaffirmed a late-September action date in its second-quarter release of August 13, 2026, pointing to a launch in the first quarter of 2027. No filing or release has followed since.

$SRRK apitegromab Sep 30 BLA SMA · Catalent Indiana removed from the BLA on August 21

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 21, 2026 the company said it had successfully removed Catalent Indiana as a commercial fill-finish facility from the BLA under FDA guidance, after Catalent notified customers on August 7 that its April inspection had been classified Official Action Indicated. In the same August 21 update Scholar Rock confirmed the action date as unchanged, said the European marketing authorisation application had been withdrawn following the CHMP written procedure of August 20 and would be resubmitted with the alternative site, and pointed to a Japanese filing by the end of 2026. Manufacturing and CMC risk therefore stays central to this review.

$ROIV brepocitinib Q3 NDA Dermatomyositis · Priority Review, exact day never disclosed

Priovant / Roivant. The brepocitinib NDA in dermatomyositis is under Priority Review. The acceptance release of March 3, 2026 states a target action date in the third quarter of 2026 and no exact day has ever been made public. Roivant’s quarterly update of August 6, 2026 describes the application as still under review and points to a commercial launch by the end of September if approval arrives.

$QURE AMT-130 Q3 BLA Huntington’s disease · filing plus four-year data in September

uniQure. The AMT-130 accelerated-approval BLA in Huntington’s disease was still to be filed as of August 25; the July 29, 2026 quarterly update describes U.S. and U.K. submissions as on track for the third quarter. Official minutes of the Type B meeting received in July confirm alignment on a filing based on existing clinical data with comparison to an external control, while the design of the confirmatory study was still being discussed. Topline four-year data from the Phase I/II study are expected in September 2026, which makes the quarter dense for this programme.

$IMMX NXC-201 Late Sep Data NEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026, a window stated in the company release of May 21, 2026. Enrolment of 45 patients is complete, as confirmed in the Form 10-Q of August 7, 2026, and one-year follow-up data due by the end of March 2027 are expected to guide the BLA. The programme is designed to be registrational.

$KPTI selinexor combo Aug sNDA Selinexor plus ruxolitinib filing in myelofibrosis

Karyopharm. The company plans to submit the selinexor plus ruxolitinib sNDA in myelofibrosis during August under the accelerated-approval pathway, requesting Priority Review at the same time; FDA has given written feedback that SVR35 appears to qualify as a reasonably likely surrogate endpoint. The plan was reaffirmed in the second-quarter release of August 13, 2026 and no announcement confirming the submission has appeared since, so the filing itself is still the open event. The former endometrial-cancer catalyst is closed: XPORT-EC-042 missed its primary progression-free-survival endpoint on July 30.

$KOD DAYBREAK Sep Phase 3 Wet AMD · Zenkuda and KSI-501 against aflibercept

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026, a guidance restated in the second-quarter release of August 13, 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel arms against aflibercept, and enrolment is complete. Cash stood at 125.9 million dollars at June 30 with runway stated into 2027, which raises the stakes on the readout.

$ALMS envudeucitinib Q3 Data LUMUS Phase 2b in systemic lupus erythematosus

Alumis. Potentially pivotal Phase 2b LUMUS results for envudeucitinib in systemic lupus erythematosus are expected in the third quarter, guidance repeated in the second-quarter release of August 13, 2026. The study is randomised, double-blind and placebo-controlled with BICLA as the primary endpoint. Decisions on Sjogren’s and cutaneous lupus are explicitly tied to this outcome, and for an autoimmune readout the market will weigh dose consistency and safety alongside statistical significance.

$IVVD VYD2311 Late Q3 Data DECLARATION pivotal study · enrolment complete

Invivyd. Topline data from the pivotal DECLARATION study of VYD2311 are planned later in the third quarter of 2026, per the second-quarter release of August 13, 2026, which also describes the study as approaching its planned analysis after being upsized to roughly 2,400 participants. Topline from LIBERTY is guided to the same window. Cash of 160.1 million dollars is stated as sufficient through the DECLARATION readout, and the company has flagged the July notice terminating the PEMGARDA emergency use authorisation with twelve months’ notice.

$PHVS deucrictibant XR Q3 Phase 3 CHAPTER-3 · hereditary angioedema prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis are expected in the third quarter of 2026, confirmed in the Form 6-K release of August 12, 2026, which puts randomisation at 85 participants assigned two to one to 40 mg daily or placebo over 24 weeks. It is one of the quarter’s most important registrational HAE readouts. Separately, the immediate-release NDA carries a PDUFA date of April 23, 2027.

$SYRE SPY003 Sep Data SKYLINE Part A in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study are expected in September 2026, as stated in the second-quarter release of August 4, 2026; enrolment of Part A is complete and SPY003 is the last of the three readouts, after SPY001 and SPY002 in April and June. The RA sub-study of SKYWAY is guided to the same month. With 1.145 billion dollars in cash and runway into the second half of 2029, financing risk is not the issue here.

$VERA TRUTAKNA / atacicept Q3 eGFR ORIGIN 3 final efficacy analysis

Vera Therapeutics. The ORIGIN 3 final efficacy analysis is expected in the third quarter, as restated in the second-quarter release of August 10, 2026. It follows the accelerated approval of TRUTAKNA (atacicept-vymj) on July 7, 2026, which rested on proteinuria, while ORIGIN 3 continues blinded and placebo-controlled with eGFR as the confirmatory endpoint. The timing was pulled forward from 2027 after alignment with FDA announced on June 2, 2026, and a supplemental BLA is guided to the fourth quarter. This is not another approval decision: what matters is the durability of the renal effect and the read-through for the confirmatory pathway.

$XENE azetukalner Q3 NDA Focal-onset seizure filing after the pre-NDA meeting

Xenon. The azetukalner NDA submission in focal-onset seizures is on track for the third quarter following the pre-NDA meeting with FDA, as stated in the second-quarter release of August 6, 2026. The application had not been filed as of August 25. Filing confirmation would open FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIO infigratinib Aug 10 NDA submitted Achondroplasia · FDA filing acceptance is the next step

BridgeBio. BridgeBio confirmed on August 10, 2026 that it had submitted the NDA for oral infigratinib in achondroplasia, and its own pipeline table lists the next milestone as FDA setting a PDUFA date. Neither filing acceptance nor a PDUFA date had been announced as of August 25, so the programme stays on the board with the regulatory process materially open. Infigratinib holds Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations, U.S. launch is guided to mid-2027 and a European application is planned for the fourth quarter.

$MLTX sonelokimab Late Sep BLA Hidradenitis suppurativa filing after positive IZAR-1

MoonLake. The sonelokimab BLA in hidradenitis suppurativa is expected around the end of September 2026, with the company guiding to a PDUFA date allocation and a decision on Priority Review by the end of November. The milestone table sits in the August 10, 2026 release that also carried positive topline results from the Phase 3 IZAR-1 trial. The filing had not been announced as of August 25.

$BNTX pumitamig · WCLC Sep 12-15 Data WCLC 2026 · PRESERVE-003 overall survival update

BioNTech. On August 20, 2026 the company disclosed its programme for the World Conference on Lung Cancer in Seoul, held from September 12 to 15, 2026. It includes a late-breaking oral presentation with the first data on the combination of pumitamig and elfetabart drozuntecan, and an overall survival update from the Phase 3 PRESERVE-003 study of gotistobart in squamous non-small cell lung cancer. Conference presentations are not regulatory events, but for this programme they are the readout of the quarter.

$SMMT ivonescimab · WCLC Sep 15 Data WCLC 2026 · updated HARMONi overall survival, two months before the PDUFA

Summit Therapeutics. On August 25, 2026 Summit said the updated overall-survival follow-up from the global Phase III HARMONi study will be presented at the IASLC World Conference on Lung Cancer on September 15, 2026, in session OA14, abstract OA14.04. The same day the company announced publication of the HARMONi primary analysis in The Lancet Oncology: median progression-free survival 6.8 against 4.4 months, hazard ratio 0.52 (95% CI 0.41–0.66; p<0.0001), with the primary overall-survival analysis showing a positive trend that did not reach statistical significance. The FDA has told the company a statistically significant overall-survival benefit is necessary in this setting, which is what makes a survival update three weeks before the November 14 target action date the readout to watch. Partner Akeso separately reported a statistically significant overall-survival benefit in first-line advanced biliary tract cancer (HARMONi-GI1), a single-region China study run and analysed by Akeso.

$RGNX RGX-202 · Duchenne Q3 BLA Duchenne BLA submission still guided to this quarter, after the RGX-121 hold

REGENXBIO. On August 24, 2026 the FDA placed a clinical hold on the Phase I/II/III trial of RGX-121 in mucopolysaccharidosis type II, following asymptomatic spine MRI findings in five participants of the CAMPSIITE study, and the company said it does not expect to resubmit the RGX-121 Biologics License Application in the near term. In the same release it stated that the Duchenne and retinal programmes use a different capsid and different routes of administration, and that their near-term catalysts are on track: the planned submission of the Duchenne BLA this quarter, and wet AMD topline pivotal data in the fourth quarter. Investigators deemed the spine findings non-serious and radiologists believe they are likely benign; no brain nodules or masses were identified. The stock fell sharply on the hold, which makes the Duchenne filing the near-term item that either confirms or undermines the company’s separation of the two programmes.

$GOSS seralutinib Sep NDA PAH filing tied to a 125 million dollar financing tranche

Gossamer Bio. On August 21, 2026 the company said it expects to submit the seralutinib NDA in pulmonary arterial hypertension in September 2026. The filing carries a direct financial consequence: the 250 million dollar private placement announced alongside it is structured so that a second tranche of roughly 125 million dollars unlocks on FDA acceptance of the application within 2026. Submission and acceptance are therefore two distinct events to track.

Most attention-worthy watchlist

$NRXP $PTGX $GILD $RARE $IONS $GRAL $MIRM $SRRK $PHVS $QURE $IMMX

Board rule

Only future or still materially unresolved catalysts through September are shown; catalysts resolved in the past few days are retained briefly for continuity. $JAZZ/Ziihera stays for one update: the FDA approved it on August 25 in first-line HER2-positive gastroesophageal adenocarcinoma, on its goal date. $CAPR has been removed from the grid. On August 24 the FDA extended the deramiocel PDUFA target action date from August 22 to November 22, 2026, after Capricor filed a BLA amendment with 24-month HOPE-3 open-label-extension data supporting a refined indication focused on upper limb function; CBER classified the submission as a major amendment. The new date falls outside the window this widget covers. $REGN/Pasatru and $RARE/GENGLYCOS have rolled off after one update: both were approved on August 19, the second for FOP and the first gene therapy in Ultragenyx history respectively. $PTGX has been corrected from Q3 back to August. The company’s own second-quarter release and Form 10-Q of August 5 both state a target action date in August 2026, which supersedes the March 2 wording of a third-quarter goal date; the exact day has never been published and no decision has been announced. $SRRK has been corrected as well: the removal of Catalent Indiana from the BLA was announced on August 21, not on August 7, which is the date Catalent notified customers of the Official Action Indicated classification. $BNTX and $GOSS join the board: BioNTech disclosed its WCLC programme on August 20 with a PRESERVE-003 overall survival update, and Gossamer Bio guided on August 21 to a September seralutinib filing. $NRXP remains because the manufacturer vial attestation has been submitted but no new exact action date has been disclosed and no company release has followed since August 17. $KPTI stays on an August window because no announcement confirming the selinexor plus ruxolitinib submission has been found, and $BBIO stays because filing acceptance for infigratinib is still the next formal step. Month-only and quarter-only windows reflect disclosed guidance and are not exact FDA dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.